5F-PB-22
Also called 5-fluoro-PB-22, 5F-QUPIC, Quinolin-8-yl 2-fluoro-1-pentyl-1H-indole-3-carboxylate
Dosage
Smoked bands as drawn from PsychonautWiki's ranges below. The table is the source of truth.
When sources disagree, both rows are shown as published. Nothing is averaged or merged.
Smoked
Oral
| Source | Threshold | Light | Common | Strong | Heavy |
|---|---|---|---|---|---|
| PsychonautWiki | 1 mg PW | 1–3 mg PW | 3–5 mg PW | 5–8 mg PW | 8 mg+ PW |
| TripSit | 1 mg TS | 1–3 mg TS | 3–5 mg TS | 5–8 mg. TS | – |
Note: As with all research chemicals, start with a low dose, and work your way up. TS
TripSit dose text
TripSit's factsheet also states its doses as text.
Threshold: 1mg Light: 1-3mg Common: 3-5mg Strong: 5-8mg. | Note: As with all research chemicals, start with a low dose, and work your way up. TS
What dose are you on? (self-reported, unverified)
No reports yet.
Reports are anonymous, one per browser per day per route. Counts under 20 are shown but marked as too few to mean anything. Until accounts launch, reports stay in this browser only.
Duration
Smoked, drawn at the midpoint of each PsychonautWiki range.
| Route · source | Onset | Come-up | Peak | Offset | Total | After-effects |
|---|---|---|---|---|---|---|
| Smoked · PsychonautWiki | 10 seconds PW | – | 30 minutes PW | 1 hour PW | 90 minutes PW | 15 minutes PW |
| Oral · PsychonautWiki | 30 minutes PW | – | 1.5 hours PW | 1 hours PW | 2–3 hours PW | 30 minutes PW |
TripSit factsheet
Mixing
Acute combinations: what happens when these are taken close together. Entries backed by a medical journal or agency are listed first.
Backed by medical journals
PsychonautWiki also lists dangerous combinations shared across a whole group (cannabis) in a table this page does not copy. Read that list on PsychonautWiki.
Risks and toxicity
The toxicity and long-term health effects of recreational 5F-PB-22 use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 5F-PB-22 has very little history of human usage. Informal experiments have shown that overdose will cause physical discomfort including heart palpitations, vertigo and sedation at much lower than dangerous doses, usually causing the user to suffer large amounts of anxiety or to fall asleep. PW
There have been many hospital reports involving 5F-PB-22, as well as cases of post-mortem analysis involving 5F-PB-22. Five deaths have been associated with the use of 5F-PB-22 in the United States.[7]
It has often been recommended that those with severe pre-existing mental conditions should not ingest these substances due to the way they strongly increase one's current state of mind and emotions. Also, like THC, prolonged usage of synthetic cannabinoids may increase one's disposition to mental illness and psychosis, particularly in vulnerable individuals with risk factors for psychotic illnesses (like a past or family history of schizophrenia).[9–12] PW
As synthetic cannabinoids are active in the milligram range (with below 5mg being a common dose), it is important to use proper precautions when dosing to avoid a negative experience. PW
It is strongly recommended that one use harm reduction practices when using this drug. PW
Tolerance and addiction potential
As with other synthetic cannibanoids, the chronic use of 5F-PB-22 can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. PW
Tolerance to many of the effects of 5F-PB-22 develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 5F-PB-22 presents cross-tolerance with all cannabinoids, meaning that after the consumption of 5F-PB-22 all cannabinoidss will have a reduced effect. PW
Testing
Effects
Overview
5F-PB-22 (1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester also known as 5F-QUPIC) is a synthetic cannabinoid and agonist of the cannabinoid receptors which produces predominantly sedating subjective effects somewhat similar to that of cannabis. There is very little information regarding the pharmacology of this compound within the scientific literature. Despite this, however, it has been sold as a grey area research chemical through online vendors.[1]
Synthetic cannabinoid, agonist of the cannabinoid receptors which has a strong sedating aspect. Being a synthetic cannabinoid it has a very fast onset. TS
5F-PB-22 (5F-QUPIC or Quinolin-8-yl 1-fluoroPentyl-1H-Indole-3-8-Carboxylate) is a designer drug which acts as a cannabinoid agonist. The structure of 5F-PB-22 appears to have been designed with an understanding of structure–activity relationships within the indole class of cannabinoids.[4]
The indazole analogue 5F-NPB-22 (5F-QUPINAC) is known.[6] WP
History
Legal status
- 5F-PB-22 was developed to bypass drug prohibition laws which have banned the possession and sale of many synthetic cannabinoids. As such, it remains legal in many parts of the world. PW
- China: As of October 2015 5F-PB-22 is a controlled substance in China.[13] PW
- Germany: 5F-PB-22 is controlled under Anlage II BtMG (Narcotics Act, Schedule II) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[14]
[15] [16] PW - Latvia: 5F-PB-22 is a Schedule I controlled substance.[17] PW
- Switzerland: 5F-PB-22 is a controlled substance specifically named under Verzeichnis D.[18] PW
- United Kingdom: 5F-PB-22 is a Class B controlled substance under the third-generation synthetic cannabinoids generic definition, which came into effect on December 14, 2016 and is illegal to possess, produce, supply, or import.[19] PW
- United States: In January 2014, 5F-PB-22 was designated as a Schedule I controlled substance in the United States.[20] PW
Legal status
As of October 2015 5F-PB-22 is a controlled substance in China.[13] WP
In January 2014, 5F-PB-22 was designated as a Schedule I controlled substance in the United States after several deaths were associated with its use.[7]
In the United Kingdom, 5F-PB-22 is now classified and controlled as a Class B drug, following the November 2016 amendment to the Misuse of Drugs Act 1971. Several other synthetic cannabinoids structurally related to JWH-018, like 5F-PB-22, were also classified in this amendment.[22] WP
Pharmacology
Pharmacology
5F-PB-22 acts as a full agonist with a binding affinity of 0.468 nM at CB₁ and 0.633 nM at CB₂ cannabinoid receptors.[23] WP
Chemistry
User reports
Erowid erowid.org
ListingsBluelight bluelight.org
ListingsReddit reddit.com
ListingsPop culture
No references added yet.
Add a reference
Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.
Opens when accounts launch.
References
- Journal / agency Wohlfarth, A., Gandhi, A. S., Pang, S., Zhu, M., Scheidweiler, K. B., Huestis, M. A. Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Analytical and Bioanalytical Chemistry. 1 February 2014. doi:10.1007/s00216-014-7668-0
- Other https://www.caymanchem.com/msdss/13169m.pdf
- Other http://www.publish.csiro.au/nid/51
- Journal / agency Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M. Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience. August 2015. doi:10.1021/acschemneuro.5b00107 · PMID 25921407
- Other 5F-PB-22
- Other 5-fluoro NPB-22 (CAS 1445579-79-2)
- Journal / agency Behonick, G., Shanks, K. G., Firchau, D. J., Mathur, G., Lynch, C. F., Nashelsky, M., Jaskierny, D. J., Meroueh, C. Four Postmortem Case Reports with Quantitative Detection of the Synthetic Cannabinoid, 5F-PB-22. Journal of Analytical Toxicology. October 2014. doi:10.1093/jat/bku048
- Harm reduction site Synthetic cannabinoids in Europe
- Journal / agency Arseneault, L., Cannon, M., Witton, J., Murray, R. M. Causal association between cannabis and psychosis: examination of the evidence. The British Journal of Psychiatry. February 2004. doi:10.1192/bjp.184.2.110
- Journal / agency Every-Palmer, S. Synthetic cannabinoid JWH-018 and psychosis: An explorative study. Drug and Alcohol Dependence. September 2011. doi:10.1016/j.drugalcdep.2011.01.012
- Journal / agency Schneir, A. B., Cullen, J., Ly, B. T. “Spice” Girls: Synthetic Cannabinoid Intoxication. The Journal of Emergency Medicine. 1 March 2011. doi:10.1016/j.jemermed.2010.10.014
- Journal / agency Vearrier, D., Osterhoudt, K. C. A Teenager With Agitation: Higher Than She Should Have Climbed. Pediatric Emergency Care. June 2010. doi:10.1097/PEC.0b013e3181e4f416
- Journal / agency 关于印发《非药用类麻醉药品和精神药品列管办法》的通知. 27 September 2015
- Other Anlage II BtMG
- Other Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften
- Other § 29 BtMG
- Other Zaudējis spēku - Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem
- Other Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien
- Other The Misuse of Drugs Act 1971 (Amendment) Order 2016
- Other http://www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr0110_10.htm
- Journal / agency Trecki J, Gerona RR, Schwartz MD. Synthetic Cannabinoid-Related Illnesses and Deaths. The New England Journal of Medicine. July 2015. doi:10.1056/NEJMp1505328 · PMID 26154784
- Other The Misuse of Drugs Act 1971 (Amendment) Order 2016
- Journal / agency Hess C, Schoeder CT, Pillaiyar T, Madea B, Müller CE. Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. Forensic Toxicology. 1 July 2016. doi:10.1007/s11419-016-0320-2 · PMID 27429655 · PMC4929166
Text and values on this page are quoted from PsychonautWiki (CC BY-SA 4.0), Wikipedia (CC BY-SA 4.0), TripSit factsheets. Each value links to the exact revision it came from.